TARS earnings analysis
What we found in TARS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Tarsus Pharmaceuticals reported strong Q1 2026 results with revenues reaching $162.1M, significantly above analyst expectations of $149.8M. The net loss improved to -$6.97M from -$25.12M year-over-year, indicating reduced operating expenses despite the increase in revenues. The company emphasized the robust sales performance of XDEMVY, demonstrating over 85% growth year-over-year, while reaffirming its 2026 revenue guidance for net sales between $670M and $700M.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue Growth Exceeds Expectations
- Revenue was reported at $162.1 million, beating estimates of $149.8 million.
- Improved EPS Performance
- Diluted EPS came in at -$0.16, better than the -$0.39 expected by analysts.
- Strong Year-over-Year Sales Increase
- XDEMVY sales reached $145.4 million, marking over an 85% increase from the prior year.
- Positive Guidance for 2026
- Management reaffirmed XDEMVY net product sales guidance of $670M to $700M.
- Reduced Net Loss
- Net loss for the quarter was -$6.97 million, a significant improvement from -$25.12 million the prior year.
- Effective Cost Management
- Despite increased revenue, total operating expenses increased modestly, highlighting effective cost control.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High SG&A Expenses
- Selling, general, and administrative expenses soared to $136.4 million from $85.0 million year-over-year.
- Increase in R&D Spending
- Research and development expenses jumped by $7.9 million, indicating a potential strain on future profits.
- Dependence on Third-Party Manufacturers
- Reliance on single suppliers for critical components of XDEMVY raises manufacturing risk.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.16
- Gross margin
- 95.3%
- Operating margin
- -3.8%
What they said about what is next.
Management reaffirmed full-year 2026 revenue guidance for XDEMVY net product sales.
The filing reads better than the one before it.
What came before.
- 10-K · February 23, 2026
- Tarsus positions itself as a commercial-stage ophthalmology-focused biopharma whose launch product XDEMVY has rapidly scaled since launch in August 2023. The company reports sustained high gross margins (~93%),…
- 10-Q · May 1, 2025
- Tarsus reported Q1 revenue of $78.335M (product sales $78.335M) versus $27.614M year-ago, a large y/y increase of $50.721M. Gross margin remained strong at ~93.4% and operating loss narrowed to -33.6% of revenue, but…
- 10-K · February 25, 2025
- Tarsus is a commercial-stage biopharma focused on eye care that launched XDEMVY (lotilaner ophthalmic solution) after FDA approval in July 2023 and commercial launch in August 2023. The company shows rapid revenue…
- 10-Q · November 9, 2023
- Tarsus reported Q3 revenue of $1,871,000 (product sales $1,653,000) following FDA approval and commercial launch of XDEMVY on August 24, 2023. Net loss widened to $39,148,000 (EPS $(1.28)) vs. $(22,511,000) (EPS…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TARS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever